Suppr超能文献

鉴定间变性淋巴瘤激酶 (ALK)+和 ALK-间变性大细胞淋巴瘤中差异表达和具有功能活性的 microRNA。

Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

机构信息

Laboratory for Immunological and Molecular Cancer Research, Third Medical Department with Hematology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.

出版信息

Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16228-33. doi: 10.1073/pnas.1009719107. Epub 2010 Aug 30.

Abstract

Aberrant anaplastic lymphoma kinase (ALK) expression is a defining feature of many human cancers and was identified first in anaplastic large-cell lymphoma (ALCL), an aggressive non-Hodgkin T-cell lymphoma. Since that time, many studies have set out to identify the mechanisms used by aberrant ALK toward tumorigenesis. We have identified a distinct profile of micro-RNAs (miRNAs) that characterize ALCL; furthermore, this profile distinguishes ALK(+) from ALK(-) subtypes, and thus points toward potential mechanisms of tumorigenesis induced by aberrant ALK. Using a nucleophosmin-ALK transgenic mouse model as well as human primary ALCL tumor tissues and human ALCL-derived cell lines, we reveal a set of overlapping deregulated miRNAs that might be implicated in the development and progression of ALCL. Importantly, ALK(+) and ALK(-) ALCL could be distinguished by a distinct profile of "oncomirs": Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL. Moreover, miR-101 was down-regulated in all ALCL model systems, but its forced expression attenuated cell proliferation only in ALK(+) and not in ALK(-) cell lines, perhaps suggesting different modes of ALK-dependent regulation of its target proteins. Furthermore, inhibition of mTOR, which is targeted by miR-101, led to reduced tumor growth in engrafted ALCL mouse models. In addition to future therapeutical and diagnostic applications, it will be of interest to study the physiological implications and prognostic value of the identified miRNA profiles.

摘要

异常的间变性淋巴瘤激酶(ALK)表达是许多人类癌症的一个特征,首先在间变性大细胞淋巴瘤(ALCL)中被鉴定出来,这是一种侵袭性非霍奇金 T 细胞淋巴瘤。从那时起,许多研究都致力于确定异常 ALK 用于肿瘤发生的机制。我们已经确定了一组独特的 micro-RNAs(miRNAs),这些 miRNAs 可以用来描述 ALCL;此外,这种模式还可以区分 ALK(+)和 ALK(-)亚型,从而指向异常 ALK 诱导肿瘤发生的潜在机制。使用核仁磷酸蛋白-ALK 转基因小鼠模型以及人原发性 ALCL 肿瘤组织和人 ALCL 衍生的细胞系,我们揭示了一组重叠的失调 miRNA,这些 miRNA 可能与 ALCL 的发生和发展有关。重要的是,ALK(+)和 ALK(-) ALCL 可以通过一组独特的“oncomirs”来区分:miR-17-92 簇的五个成员在 ALK(+) ALCL 中表达更高,而 miR-155 在 ALK(-) ALCL 中表达高出 10 倍以上。此外,miR-101 在所有 ALCL 模型系统中均下调,但在 ALK(+)而不是 ALK(-)细胞系中其强制表达可减弱细胞增殖,这可能表明 ALK 对其靶蛋白的调节有不同的模式。此外,抑制 mTOR(miR-101 的靶标)可导致植入的 ALCL 小鼠模型中的肿瘤生长减少。除了未来的治疗和诊断应用外,研究所鉴定的 miRNA 图谱的生理意义和预后价值也将是很有意义的。

相似文献

1
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16228-33. doi: 10.1073/pnas.1009719107. Epub 2010 Aug 30.
2
Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Blood. 2017 Feb 16;129(7):823-831. doi: 10.1182/blood-2016-05-717793. Epub 2016 Nov 22.
3
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
J Pathol. 2015 Aug;236(4):445-56. doi: 10.1002/path.4539. Epub 2015 Apr 27.
5
MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
Blood. 2013 Sep 19;122(12):2083-92. doi: 10.1182/blood-2012-08-447375. Epub 2013 Jun 25.
7
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
Blood. 2009 Jul 9;114(2):360-70. doi: 10.1182/blood-2007-11-125658. Epub 2009 May 7.
8
10
miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
Blood. 2011 Dec 22;118(26):6881-92. doi: 10.1182/blood-2011-05-354654. Epub 2011 Oct 31.

引用本文的文献

3
Updates in pathobiological aspects of anaplastic large cell lymphoma.
Front Oncol. 2023 Sep 22;13:1241532. doi: 10.3389/fonc.2023.1241532. eCollection 2023.
4
Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles.
Front Oncol. 2023 Aug 10;13:1230273. doi: 10.3389/fonc.2023.1230273. eCollection 2023.
5
Mature T-cell and NK-cell lymphomas: updates on molecular genetic features.
Int J Hematol. 2023 Apr;117(4):475-491. doi: 10.1007/s12185-023-03537-7. Epub 2023 Jan 13.
6
CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.
Leukemia. 2022 Aug;36(8):2050-2063. doi: 10.1038/s41375-022-01617-x. Epub 2022 Jun 8.
7
New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer.
Cancers (Basel). 2021 Oct 14;13(20):5149. doi: 10.3390/cancers13205149.
9
Cytokines, Genetic Lesions and Signaling Pathways in Anaplastic Large Cell Lymphomas.
Cancers (Basel). 2021 Aug 24;13(17):4256. doi: 10.3390/cancers13174256.
10
Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.
Clin Cancer Res. 2021 Nov 1;27(21):6039-6053. doi: 10.1158/1078-0432.CCR-21-0573. Epub 2021 Aug 23.

本文引用的文献

2
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
Blood. 2010 May 27;115(21):4191-7. doi: 10.1182/blood-2009-07-234823. Epub 2010 Jan 20.
3
Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
Mol Cancer Res. 2009 Sep;7(9):1466-76. doi: 10.1158/1541-7786.MCR-08-0522. Epub 2009 Sep 8.
4
EML4-ALK: honing in on a new target in non-small-cell lung cancer.
J Clin Oncol. 2009 Sep 10;27(26):4232-5. doi: 10.1200/JCO.2009.23.6661. Epub 2009 Aug 10.
6
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways.
Blood. 2009 Aug 20;114(8):1585-95. doi: 10.1182/blood-2009-02-204735. Epub 2009 Jun 16.
7
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.
Cell. 2009 Jun 12;137(6):1005-17. doi: 10.1016/j.cell.2009.04.021.
9
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.
Cancer Res. 2009 Mar 15;69(6):2623-9. doi: 10.1158/0008-5472.CAN-08-3114. Epub 2009 Mar 3.
10
MicroRNAs: target recognition and regulatory functions.
Cell. 2009 Jan 23;136(2):215-33. doi: 10.1016/j.cell.2009.01.002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验